{"id":38961,"date":"2026-08-31T11:29:44","date_gmt":"2026-08-31T15:29:44","guid":{"rendered":"https:\/\/nephcure.org\/?page_id=38961"},"modified":"2026-08-31T11:40:53","modified_gmt":"2026-08-31T15:40:53","slug":"fabhalta-iptacopan-for-c3g","status":"publish","type":"page","link":"https:\/\/nephcure.org\/es\/managing-rkd\/treatment-options\/fabhalta-iptacopan-for-c3g\/","title":{"rendered":"FABHALTA\u00ae (Iptacopan)\u00a0for C3G"},"content":{"rendered":"<section class=\"gb-container gb-container-ba2e2dcb\">\n<div class=\"yoast-breadcrumbs breadcrumb\"><span><span><a href=\"https:\/\/nephcure.org\/\">Home<\/a><\/span> \/ <span><a href=\"https:\/\/nephcure.org\/managing-rkd\/\">Managing RKD<\/a><\/span> \/ <span><a href=\"https:\/\/nephcure.org\/managing-rkd\/treatment-options\/\">Treatment Options<\/a><\/span> \/ <span class=\"breadcrumb_last\" aria-current=\"page\">FABHALTA\u00ae (Iptacopan)\u00a0for C3G<\/span><\/span><\/div>\n\n<div class=\"gb-container gb-container-80071c84 hero-copy\">\n\n<h1 class=\"gb-headline gb-headline-6cf43bd0 gb-headline-text hero-content\">FABHALTA\u00ae (Iptacopan)&nbsp;<\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Iptacopan (Fabhalta) was approved by the Food and Drug Administration (FDA) in March 2025 to reduce proteinuria in adults with complement 3 glomerulopathy (C3G). It was the first medication specifically approved for the treatment of C3G.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Medically reviewed by Dr. John Sperati, MD<\/em><\/p>\n\n<\/div>\n\n<div class=\"gb-container gb-container-a6126eda\">\n\n<figure class=\"gb-block-image gb-block-image-40625f55\"><img loading=\"lazy\" decoding=\"async\" width=\"54\" height=\"4\" class=\"gb-image gb-image-40625f55\" src=\"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/11\/heading-line.svg\" alt=\"\" title=\"heading-line\"\/><\/figure>\n\n\n\n<h2 class=\"gb-headline gb-headline-88096344 gb-headline-text\">How Does FABHALTA\u00ae Work for C3G?<span style=\"caret-color: rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: -webkit-standard; font-size: medium; font-weight: 400; white-space: normal;\"><\/span><\/h2>\n\n\n\n<p class=\"gb-headline gb-headline-fb79fb92 gb-headline-text\">In C3G, part of the immune system, called the alternative pathway of complement, is too active and injures the kidneys. Iptacopan (Fabhalta) works by reducing the activity of this pathway. To reduce the activity, iptacopan binds to and prevents the function of a protein called complement factor B (CFB). CFB is important for the activation of the alternative pathway of complement. By preventing CFB from functioning properly, the alternative pathway of complement is less active. Making this pathway less active reduces the ability of the complement system to cause kidney injury in people with C3G.<\/p>\n\n\n<div class=\"gb-container gb-container-626eb763\"><\/div>\n\n\n<figure class=\"gb-block-image gb-block-image-8e308869\"><img loading=\"lazy\" decoding=\"async\" width=\"54\" height=\"4\" class=\"gb-image gb-image-8e308869\" src=\"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/11\/heading-line.svg\" alt=\"\" title=\"heading-line\"\/><\/figure>\n\n\n\n<h2 class=\"gb-headline gb-headline-3de92b95 gb-headline-text\"><strong>How is <\/strong>FABHALTA\u00ae for C3G Administered?<span style=\"caret-color: rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: -webkit-standard; font-size: medium; font-weight: 400; white-space: normal;\"><\/span><\/h2>\n\n\n\n<p class=\"gb-headline gb-headline-fd1cb896 gb-headline-text\">Iptacopan (Fabhalta) is a pill taken twice a day by mouth. It should be swallowed whole and can be taken either with or without food.<\/p>\n\n\n\n<figure class=\"gb-block-image gb-block-image-67fe5e06\"><img loading=\"lazy\" decoding=\"async\" width=\"54\" height=\"4\" class=\"gb-image gb-image-67fe5e06\" src=\"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/11\/heading-line.svg\" alt=\"\" title=\"heading-line\"\/><\/figure>\n\n\n\n<h2 class=\"gb-headline gb-headline-da1ae61d gb-headline-text\"><strong><strong>Is<\/strong> FABHALTA\u00ae for C3G Right for Me?<\/strong><span style=\"caret-color: rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: -webkit-standard; font-size: medium; font-weight: 400; white-space: normal;\"><\/span><\/h2>\n\n\n\n<p class=\"gb-headline gb-headline-c164ace3 gb-headline-text\">You should discuss with your doctor if iptacopan (Fabhalta) is right for you. Iptacopan (Fabhalta) is approved for the treatment of C3G, a disease that requires a kidney biopsy for diagnosis. Iptacopan (Fabhalta) has not been specifically approved for people younger than 18 years of age. Like all medications, iptacopan (Fabhalta) has potential side-effects that should be discussed and considered in the context of your medical conditions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>*Note: The decision to prescribe a medication is the responsibility of your physician\/medical team based on their evaluation of your condition. The above is meant for informational purposes only. Discuss this information and all information about drugs\/medications with your physician before starting or stopping any medication.<\/em>&nbsp;<\/p>\n\n<\/div>\n<\/section>\n\n<div class=\"gb-container gb-container-80f48e60\">\n\n<figure class=\"gb-block-image gb-block-image-639c7bd5\"><img loading=\"lazy\" decoding=\"async\" width=\"54\" height=\"4\" class=\"gb-image gb-image-639c7bd5\" src=\"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/11\/heading-line.svg\" alt=\"\" title=\"heading-line\"\/><\/figure>\n\n\n\n<h2 class=\"gb-headline gb-headline-bff6dfde gb-headline-text\">Frequently Asked Questions<\/h2>\n\n\n<div class=\"gb-container gb-container-3f003111 gb-accordion\">\n<div class=\"gb-container gb-container-342c972d gb-accordion__item\" data-transition=\"slide\">\n\n<button class=\"gb-button gb-button-05b57231 gb-accordion__toggle\" id=\"gb-accordion-toggle-05b57231\"><span class=\"gb-button-text\"><strong>What do studies show regarding the medication\u2019s effectiveness in C3G?<\/strong><\/span><span class=\"gb-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\" width=\"1em\" height=\"1em\" ariahidden=\"true\" role=\"img\" class=\"gb-accordion__icon\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\" fill=\"currentColor\"><\/path><\/svg><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\" width=\"1em\" height=\"1em\" ariahidden=\"true\" role=\"img\" class=\"gb-accordion__icon-open\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\" fill=\"currentColor\"><\/path><\/svg><\/span><\/button>\n\n\n<div id=\"gb-accordion-content-f9fdcd74\" class=\"gb-accordion__content\"><div class=\"gb-container gb-container-f9fdcd74\">\n\n<p class=\"wp-block-paragraph\">Iptacopan (Fabhalta) was approved based on results from the APPEAR clinical trial, a randomized, double blind Phase 3 trial of iptacopan versus placebo (dummy pill). Participants enrolled in the trial had to be 18 years or older, have an eGFR \u226530 ml\/min\/1.73m<sup>2<\/sup>, urine protein to creatinine ratio \u22651 gram\/gram, and a C3 level &lt;77 mg\/dL. Participants with kidney transplants were not included in this study. After 6 months, participants receiving iptacopan had an approximately 35% greater reduction in urine protein than those receiving placebo. Data from the APPEAR trial and other studies demonstrate iptacopan slows the loss of kidney function over 12 months.<\/p>\n\n<\/div><\/div>\n<\/div>\n\n<div class=\"gb-container gb-container-68f0eaa5 gb-accordion__item\" data-transition=\"slide\">\n\n<button class=\"gb-button gb-button-d702eeea gb-accordion__toggle\" id=\"gb-accordion-toggle-d702eeea\"><span class=\"gb-button-text\"><strong>How is iptacopan different from the other FDA approved treatments for C3G?<\/strong><\/span><span class=\"gb-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\" width=\"1em\" height=\"1em\" ariahidden=\"true\" role=\"img\" class=\"gb-accordion__icon\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\" fill=\"currentColor\"><\/path><\/svg><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\" width=\"1em\" height=\"1em\" ariahidden=\"true\" role=\"img\" class=\"gb-accordion__icon-open\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\" fill=\"currentColor\"><\/path><\/svg><\/span><\/button>\n\n\n<div id=\"gb-accordion-content-2b8161d3\" class=\"gb-accordion__content\"><div class=\"gb-container gb-container-2b8161d3\">\n\n<p class=\"wp-block-paragraph\">The only other FDA approved treatment for C3G is pegcetacoplan (Empaveli). Here is how they differ.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">How they are taken:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pegcetacoplan (Empaveli) is an under-the-skin infusion administered at home twice a week. \u00a0<\/li>\n\n\n\n<li>Iptacopan (Fabhalta) is a pill taken by mouth twice a day.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">FDA approval:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pegcetacoplan (Empaveli) is approved for people aged 12 years and older with C3G or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) to reduce proteinuria and the loss of kidney function.<\/li>\n\n\n\n<li>Iptacopan (Fabhalta) is approved for adults aged 18 years and older with C3G to reduce proteinuria.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">How they work:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The complement system has different pathways that can be overactive in people with C3G. These pathways are called: alternative, classical and lectin.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Iptacopan mostly reduces the activity of the alternative pathway. It binds and reduces the function of protein complement factor B (CFB).<\/li>\n\n\n\n<li>Pegcetacoplan works to reduce the activity of three pathways of the complement system. It binds and reduces the function of a protein called complement C3. Complement C3 is important to all three complement pathways (alternative, classical and lectin).<\/li>\n<\/ul>\n\n<\/div><\/div>\n<\/div>\n\n<div class=\"gb-container gb-container-2fcf7640 gb-accordion__item\" data-transition=\"slide\">\n\n<button class=\"gb-button gb-button-69efb835 gb-accordion__toggle\" id=\"gb-accordion-toggle-69efb835\"><span class=\"gb-button-text\"><strong>Is iptacopan safe?<\/strong><\/span><span class=\"gb-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\" width=\"1em\" height=\"1em\" ariahidden=\"true\" role=\"img\" class=\"gb-accordion__icon\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\" fill=\"currentColor\"><\/path><\/svg><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\" width=\"1em\" height=\"1em\" ariahidden=\"true\" role=\"img\" class=\"gb-accordion__icon-open\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\" fill=\"currentColor\"><\/path><\/svg><\/span><\/button>\n\n\n<div id=\"gb-accordion-content-7a4bb49d\" class=\"gb-accordion__content\"><div class=\"gb-container gb-container-7a4bb49d\">\n\n<p class=\"wp-block-paragraph\">Iptacopan (Fabhalta) has been shown to have an acceptable safety profile in clinical trials and real-world use. By reducing the activity of the complement system (part of the immune system), iptacopan (Fabhalta) may increase your risk for infection. In particular, the risk for infection with encapsulated bacteria such as <em>Neisseria<\/em> species, <em>Streptococcus pneumoniae,<\/em> and <em>Haemophilus influenzae<\/em> Type B is increased. These infections can be serious and lead to death if untreated. To help reduce the risk of infection, you must receive a series of vaccines. Some people may also need to take prophylactic (or preventative) antibiotics during iptacopan (Fabhalta) treatment.<\/p>\n\n<\/div><\/div>\n<\/div>\n\n<div class=\"gb-container gb-container-e3ce4ba9 gb-accordion__item\" data-transition=\"slide\">\n\n<button class=\"gb-button gb-button-b740906a gb-accordion__toggle\" id=\"gb-accordion-toggle-b740906a\"><span class=\"gb-button-text\"><strong><strong>What is the difference between iptacopan<\/strong> <strong>and other treatments commonly used to treat C3G?<\/strong> <em>This refers to off-label medications.<\/em><\/strong><\/span><span class=\"gb-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\" width=\"1em\" height=\"1em\" ariahidden=\"true\" role=\"img\" class=\"gb-accordion__icon\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\" fill=\"currentColor\"><\/path><\/svg><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\" width=\"1em\" height=\"1em\" ariahidden=\"true\" role=\"img\" class=\"gb-accordion__icon-open\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\" fill=\"currentColor\"><\/path><\/svg><\/span><\/button>\n\n\n<div id=\"gb-accordion-content-c8768a11\" class=\"gb-accordion__content\"><div class=\"gb-container gb-container-c8768a11\">\n\n<p class=\"wp-block-paragraph\">There are two types of medications used to treat C3G: those that suppress the immune system (immunosuppressants) and those that do not suppress the immune system (non-immunosuppressive medications).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Non-immunosuppressive medications (also called \u201cfoundational\u201d medications) are often used to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>treat high blood pressure<\/li>\n\n\n\n<li>lower urine protein<\/li>\n\n\n\n<li>slow the accumulation of scar tissue in the kidneys that leads to loss of function<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These therapies include blood pressure medications like angiotensin converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARB), sodium-glucose transporter 2 inhibitors (SGLT2 inhibitors), and mineralocorticoid receptor antagonists (MRA).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Non-immunosuppressive medications do not increase the risk for infection, but they also do not directly target the overactive complement system that injures kidneys in C3G.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Immunosuppressant medications:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Both FDA approved medications for the treatment of C3G, iptacopan (Fabhalta) and pegcetacoplan (Empaveli), are immunosuppressant medications. Both medications target the specific part of the immune system that leads to kidney damage in C3G.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Other immune suppressing therapies are sometimes used to treat C3G. This can include oral immune suppressants such as mycophenolate mofetil and prednisone (a steroid). These therapies reduce the immune system in general and may help to limit kidney injury. They do not specifically target the part of the immune system that is overactive in C3G. Some people with C3G form antibodies (other proteins in the immune system) that cause the complement system to be too active and injure kidneys. &nbsp;Immunosuppressants like mycophenolate mofetil and prednisone may reduce antibodies so they do not trigger the complement system. Like any immune suppressant, these therapies can increase the risk for infection.<\/p>\n\n<\/div><\/div>\n<\/div>\n\n<div class=\"gb-container gb-container-3ae3212c gb-accordion__item\" data-transition=\"slide\">\n\n<button class=\"gb-button gb-button-cb4ded02 gb-accordion__toggle\" id=\"gb-accordion-toggle-cb4ded02\"><span class=\"gb-button-text\"><strong><strong>How do I get iptacopan?<\/strong><\/strong><\/span><span class=\"gb-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\" width=\"1em\" height=\"1em\" ariahidden=\"true\" role=\"img\" class=\"gb-accordion__icon\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\" fill=\"currentColor\"><\/path><\/svg><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\" width=\"1em\" height=\"1em\" ariahidden=\"true\" role=\"img\" class=\"gb-accordion__icon-open\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\" fill=\"currentColor\"><\/path><\/svg><\/span><\/button>\n\n\n<div id=\"gb-accordion-content-3afec5e5\" class=\"gb-accordion__content\"><div class=\"gb-container gb-container-3afec5e5\">\n\n<p class=\"wp-block-paragraph\">Iptacopan (Fabhalta) is available only by prescription from your physician. If you take Fabhalta, both you and your prescribing doctor are required to enroll in a Risk Evaluation and Mitigation Strategy (REMS) program. You will need to receive a series of vaccines at least 2 weeks prior to starting the medication. The REMS program helps to ensure you are aware of the infection risks associated with iptacopan (Fabhalta) and have been educated on how to identify and respond to signs or symptoms of infection. Pharmaceutical assistance programs might be available to help you obtain or afford the medication.<\/p>\n\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n<div class=\"gb-container gb-container-0d21e4ac\">\n<div class=\"gb-grid-wrapper gb-grid-wrapper-3d338a55\">\n<div class=\"gb-grid-column gb-grid-column-296a2c84\"><div class=\"gb-container gb-container-296a2c84\">\n<div class=\"gb-container gb-container-eb83049f\">\n\n<h2 class=\"gb-headline gb-headline-5127a4de gb-headline-text\">Find a Specialist<\/h2>\n\n\n\n<p class=\"gb-headline gb-headline-00d5119d gb-headline-text\">It is important to work with a nephrologist who specializes in rare kidney disease (RKD) and can provide personalized advice based on your individual health needs and changes in available treatments. NephCure has a curated list of NephCure Specialists nationwide ready to help you.<\/p>\n\n<\/div>\n\n<div class=\"gb-container gb-container-54aa31c0\"><a class=\"gb-container-link\" href=\"https:\/\/nephcure.org\/managing-rkd\/find-a-specialist\/\"><\/a>\n\n<p class=\"gb-headline gb-headline-38137575\"><span class=\"gb-icon\"><svg fill=\"none\" viewBox=\"0 0 27 24\" height=\"24\" width=\"27\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"> <path fill=\"#00556B\" d=\"M26.0607 13.0607C26.6464 12.4749 26.6464 11.5251 26.0607 10.9393L16.5147 1.3934C15.9289 0.807611 14.9792 0.807611 14.3934 1.3934C13.8076 1.97919 13.8076 2.92893 14.3934 3.51472L22.8787 12L14.3934 20.4853C13.8076 21.0711 13.8076 22.0208 14.3934 22.6066C14.9792 23.1924 15.9289 23.1924 16.5147 22.6066L26.0607 13.0607ZM0 13.5H25V10.5H0V13.5Z\"><\/path> <\/svg><\/span><\/p>\n\n<\/div>\n<\/div><\/div>\n\n<div class=\"gb-grid-column gb-grid-column-00512214\"><div class=\"gb-container gb-container-00512214\">\n<div class=\"gb-container gb-container-178632bb\">\n\n<h2 class=\"gb-headline gb-headline-74b009b0 gb-headline-text\">Clinical Trials<\/h2>\n\n\n\n<p class=\"has-secondary-lighter-gray-color has-text-color has-link-color wp-elements-1 wp-block-paragraph\">From accessing cutting-edge treatments to being part of groundbreaking research, discover the benefits that can make a real difference. Learn more about clinical trials currently taking place, and find opportunities near you.<\/p>\n\n<\/div>\n\n<div class=\"gb-container gb-container-e263f928\"><a class=\"gb-container-link\" href=\"https:\/\/nephcure.org\/managing-rkd\/clinical-trials\/\"><\/a>\n\n<p class=\"gb-headline gb-headline-7dbd95e4\"><span class=\"gb-icon\"><svg fill=\"none\" viewBox=\"0 0 27 24\" height=\"24\" width=\"27\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"> <path fill=\"#00556B\" d=\"M26.0607 13.0607C26.6464 12.4749 26.6464 11.5251 26.0607 10.9393L16.5147 1.3934C15.9289 0.807611 14.9792 0.807611 14.3934 1.3934C13.8076 1.97919 13.8076 2.92893 14.3934 3.51472L22.8787 12L14.3934 20.4853C13.8076 21.0711 13.8076 22.0208 14.3934 22.6066C14.9792 23.1924 15.9289 23.1924 16.5147 22.6066L26.0607 13.0607ZM0 13.5H25V10.5H0V13.5Z\"><\/path> <\/svg><\/span><\/p>\n\n<\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n<div class=\"gb-container gb-container-42105b23 news-letter-sec alignfull\">\n\n<figure class=\"gb-block-image gb-block-image-b3f3ccb8\"><img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"120\" class=\"gb-image gb-image-b3f3ccb8\" src=\"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/11\/purple-curve.svg\" alt=\"\" title=\"purple-curve\"\/><\/figure>\n\n\n<div class=\"gb-container gb-container-41717e70 alignwide\">\n\n<h2 class=\"gb-headline gb-headline-1760ac29 gb-headline-text\">Sign up to get NephCure\u2019s latest updates.<\/h2>\n\n\n\n<a class=\"gb-button gb-button-753f318a gb-button-text gb-button-primary button\" href=\"\/newsletter\/\">SIGN UP<\/a>\n\n\n<div class=\"gb-container gb-container-2b968bcb news-letter-field\">\n    <script type=\"text\/javascript\">\n    jQuery(document).ready(function($) {\n        const disposableDomains = [\n            'mailinator.com', 'yopmail.com', 'tempmail.com', 'guerrillamail.com',\n            'throwawaymail.com', 'fakeinbox.com', 'trashmail.com', 'sharklasers.com',\n            'tempinbox.com', '10minutemail.com'\n        ];\n        const majorProviders = [\n            'gmail.com', 'yahoo.com', 'hotmail.com', 'outlook.com',\n            'aol.com', 'icloud.com', 'protonmail.com'\n        ];\n        const suspiciousUsernames = [\n            'test', 'example', 'user', 'admin', 'info', 'mail', 'email',\n            'noreply', 'no-reply', 'donotreply', 'do-not-reply', 'fake',\n            'abc', '123', 'xyz', 'asdf', 'qwerty', 'demo', 'sample',\n            'spam', 'temp', 'dummy', 'foobar', 'anonymous', 'disposable'\n        ];\n        const keyboardPatterns = ['qwerty', 'asdfgh', 'zxcvbn', '123456'];\n\n        function isValidEmailFormat(email) {\n            const regex = \/^[^\\s@]+@[^\\s@]+\\.[^\\s@]+$\/;\n            return regex.test(email);\n        }\n\n        function hasSuspiciousPattern(username) {\n            if (suspiciousUsernames.includes(username)) return true;\n            if (username.length <= 2) return true;\n            if (\/^(.)\\1{3,}$\/.test(username)) return true;\n            for (const pattern of keyboardPatterns) {\n                if (username.includes(pattern)) return true;\n            }\n            return false;\n        }\n\n        function usernameMatchesDomain(username, domain) {\n            const domainBase = domain.split('.')[0];\n            return username === domainBase;\n        }\n\n        $('.ginput_container_email input').on('blur', function() {\n            const emailField = $(this);\n            const email = emailField.val().trim().toLowerCase();\n            const errorContainer = emailField.siblings('.validation_message');\n\n            \/\/ Clear any previous messages\n            if (errorContainer.length) errorContainer.remove();\n            emailField.removeClass('gfield_error gfield_warning');\n\n            if (email === '') return;\n\n            const username = email.substring(0, email.lastIndexOf('@'));\n            const domain = email.substring(email.lastIndexOf('@') + 1);\n\n            if (!isValidEmailFormat(email)) {\n                emailField.after('<div class=\"validation_message\">Please enter a valid email address.<\/div>');\n                emailField.addClass('gfield_error');\n                return;\n            }\n\n            if (disposableDomains.includes(domain)) {\n                emailField.after('<div class=\"validation_message\">Disposable email addresses are not allowed.<\/div>');\n                emailField.addClass('gfield_error');\n                return;\n            }\n\n            if (usernameMatchesDomain(username, domain)) {\n                emailField.after('<div class=\"validation_message\">This email looks suspicious (username matches domain). Please provide a valid email.<\/div>');\n                emailField.addClass('gfield_error');\n                return;\n            }\n\n            if (majorProviders.includes(domain)) {\n                if (hasSuspiciousPattern(username)) {\n                    emailField.after('<div class=\"validation_message\">Username looks suspicious. Please use a valid personal email.<\/div>');\n                    emailField.addClass('gfield_warning');\n                }\n            }\n\n            \/\/ \u2705\u00a0Custom domains pass unless caught on backend\n        });\n    });\n    <\/script>\n    <script>\nvar gform;gform||(document.addEventListener(\"gform_main_scripts_loaded\",function(){gform.scriptsLoaded=!0}),document.addEventListener(\"gform\/theme\/scripts_loaded\",function(){gform.themeScriptsLoaded=!0}),window.addEventListener(\"DOMContentLoaded\",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,themeScriptsLoaded:!1,isFormEditor:()=>\"function\"==typeof InitializeEditor,callIfLoaded:function(o){return!(!gform.domLoaded||!gform.scriptsLoaded||!gform.themeScriptsLoaded&&!gform.isFormEditor()||(gform.isFormEditor()&&console.warn(\"The use of gform.initializeOnLoaded() is deprecated in the form editor context and will be removed in Gravity Forms 3.1.\"),o(),0))},initializeOnLoaded:function(o){gform.callIfLoaded(o)||(document.addEventListener(\"gform_main_scripts_loaded\",()=>{gform.scriptsLoaded=!0,gform.callIfLoaded(o)}),document.addEventListener(\"gform\/theme\/scripts_loaded\",()=>{gform.themeScriptsLoaded=!0,gform.callIfLoaded(o)}),window.addEventListener(\"DOMContentLoaded\",()=>{gform.domLoaded=!0,gform.callIfLoaded(o)}))},hooks:{action:{},filter:{}},addAction:function(o,r,e,t){gform.addHook(\"action\",o,r,e,t)},addFilter:function(o,r,e,t){gform.addHook(\"filter\",o,r,e,t)},doAction:function(o){gform.doHook(\"action\",o,arguments)},applyFilters:function(o){return gform.doHook(\"filter\",o,arguments)},removeAction:function(o,r){gform.removeHook(\"action\",o,r)},removeFilter:function(o,r,e){gform.removeHook(\"filter\",o,r,e)},addHook:function(o,r,e,t,n){null==gform.hooks[o][r]&&(gform.hooks[o][r]=[]);var d=gform.hooks[o][r];null==n&&(n=r+\"_\"+d.length),gform.hooks[o][r].push({tag:n,callable:e,priority:t=null==t?10:t})},doHook:function(r,o,e){var t;if(e=Array.prototype.slice.call(e,1),null!=gform.hooks[r][o]&&((o=gform.hooks[r][o]).sort(function(o,r){return o.priority-r.priority}),o.forEach(function(o){\"function\"!=typeof(t=o.callable)&&(t=window[t]),\"action\"==r?t.apply(null,e):e[0]=t.apply(null,e)})),\"filter\"==r)return e[0]},removeHook:function(o,r,t,n){var e;null!=gform.hooks[o][r]&&(e=(e=gform.hooks[o][r]).filter(function(o,r,e){return!!(null!=n&&n!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][r]=e)}});\n<\/script>\n\n                <div class='gf_browser_gecko gform_wrapper gravity-theme gform-theme--no-framework' data-form-theme='gravity-theme' data-form-index='0' id='gform_wrapper_22' ><form method='post' enctype='multipart\/form-data'  id='gform_22'  action='\/es\/wp-json\/wp\/v2\/pages\/38961' data-formid='22' novalidate>\n                        <div class='gform-body gform_body'><div id='gform_fields_22' class='gform_fields top_label form_sublabel_below description_below validation_below' data-column-layout='fill'><div id=\"field_22_2\" class=\"gfield gfield--type-honeypot gform_validation_container field_sublabel_below gfield--has-description field_description_below field_validation_below gfield_visibility_visible\"><label id='gfield_label_22_2' class='gfield_label gform-field-label' for='input_22_2'><span class='gform-field-label__text'>X\/Twitter<\/span><\/label><div class='ginput_container'><input name='input_2' id='input_22_2' type='text' value='' autocomplete='new-password'\/><\/div><div class='gfield_description' id='gfield_description_22_2'>This field is for validation purposes and should be left unchanged.<\/div><\/div><div id=\"field_22_1\" class=\"gfield gfield--type-email gfield--width-half gfield_contains_required field_sublabel_below gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\" data-group-id=\"567d170e\" data-field-span=\"6\"><label id='gfield_label_22_1' class='gfield_label gform-field-label' for='input_22_1'><span class='gform-field-label__text'>Email<\/span><span class=\"gfield_required\"><span class=\"gfield_required gfield_required_text\">(Required)<\/span><\/span><\/label><div class='ginput_container ginput_container_email'>\n                            <input name='input_1' id='input_22_1' type='email' value='' class='large'   placeholder='email@address.com' aria-required=\"true\" aria-invalid=\"false\"  \/>\n                        <\/div><\/div><div id=\"field_submit_22\" class=\"gfield gfield--type-submit gfield--width-half field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible\" data-field-class=\"gform_editor_submit_container\" data-field-position=\"inline\"><button type='submit' id='gform_submit_button_22' onclick='gform.submission.handleButtonClick(this);' data-submission-type='submit' class='gform-button gform-button--white  button gform_image_button'  ><img src='https:\/\/nephcure.org\/wp-content\/uploads\/2023\/12\/Arrow-6.svg' alt='Submit'><\/button><\/div><\/div><\/div>\n        <div class='gform-footer gform_footer top_label'>  \n            <input type='hidden' class='gform_hidden' name='gform_submission_method' data-js='gform_submission_method_22' value='postback' \/>\n            <input type='hidden' class='gform_hidden' name='gform_theme' data-js='gform_theme_22' id='gform_theme_22' value='gravity-theme' \/>\n            <input type='hidden' class='gform_hidden' name='gform_style_settings' data-js='gform_style_settings_22' id='gform_style_settings_22' value='{&quot;inputPrimaryColor&quot;:&quot;#204ce5&quot;}' \/>\n            <input type='hidden' class='gform_hidden' name='is_submit_22' value='1' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submit' value='22' \/>\n            \n            <input type='hidden' class='gform_hidden' name='gform_currency' data-currency='USD' value='9RmzUT7eM1eSEW8236Gt7i59NATgVBFSEqr2z1MuguGGaNRMFVthmmwAQ\/DUDsUizKIR\/e0xhJe+5Y0IQYz2+i8QHO1JVCc6mDDpFX28Ie4so9Y=' \/>\n            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' \/>\n            <input type='hidden' class='gform_hidden' name='state_22' value='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' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_target_page_number_22' id='gform_target_page_number_22' value='0' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_source_page_number_22' id='gform_source_page_number_22' value='1' \/>\n            <input type='hidden' name='gform_field_values' value='' \/>\n            \n        <\/div>\n                        <\/form>\n                        <\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>FABHALTA\u00ae (Iptacopan)&nbsp; Iptacopan (Fabhalta) was approved by the Food and Drug Administration (FDA) in March 2025 to reduce proteinuria in adults with complement 3 glomerulopathy (C3G). It was the first &#8230; <a title=\"FABHALTA\u00ae (Iptacopan)\u00a0for C3G\" class=\"read-more\" href=\"https:\/\/nephcure.org\/es\/managing-rkd\/treatment-options\/fabhalta-iptacopan-for-c3g\/\" aria-label=\"Leer m\u00e1s sobre FABHALTA\u00ae (Iptacopan)\u00a0for C3G\">Leer m\u00e1s<\/a><\/p>","protected":false},"author":12083,"featured_media":33797,"parent":24621,"menu_order":8,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"disease-category":[255],"topic":[],"treatment-option":[676],"hf_cat_page":[339],"class_list":["post-38961","page","type-page","status-publish","has-post-thumbnail","disease-category-iga-nephropathy-igan","treatment-option-fabhalta-iptacopan"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.8 (Yoast SEO v28.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FABHALTA\u00ae (Iptacopan)\u00a0for C3G - NephCure<\/title>\n<meta name=\"description\" content=\"Learn more about FABHALTA\u00ae (Iptacopan), a FDA approved treatment for IgA Nephropathy (IgAN) patients that helps lower proteinuria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/fabhalta-iptacopan-for-c3g\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FABHALTA\u00ae (Iptacopan)\u00a0for C3G\" \/>\n<meta property=\"og:description\" content=\"Learn more about FABHALTA\u00ae (Iptacopan), a FDA approved treatment for IgA Nephropathy (IgAN) patients that helps lower proteinuria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/fabhalta-iptacopan-for-c3g\/\" \/>\n<meta property=\"og:site_name\" content=\"NephCure\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/nephcure\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-31T15:40:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/08\/NephCure_Simple_Logo_RBG.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"371\" \/>\n\t<meta property=\"og:image:height\" content=\"467\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@nephcure\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutos\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FABHALTA\u00ae (Iptacopan)\u00a0for C3G - NephCure","description":"Obtenga m\u00e1s informaci\u00f3n sobre FABHALTA\u00ae (Iptacopan), un tratamiento aprobado por la FDA para pacientes con nefropat\u00eda por IgA (IgAN) que ayuda a reducir la proteinuria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/fabhalta-iptacopan-for-c3g\/","og_locale":"es_MX","og_type":"article","og_title":"FABHALTA\u00ae (Iptacopan)\u00a0for C3G","og_description":"Learn more about FABHALTA\u00ae (Iptacopan), a FDA approved treatment for IgA Nephropathy (IgAN) patients that helps lower proteinuria.","og_url":"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/fabhalta-iptacopan-for-c3g\/","og_site_name":"NephCure","article_publisher":"https:\/\/www.facebook.com\/nephcure\/","article_modified_time":"2026-08-31T15:40:53+00:00","og_image":[{"width":371,"height":467,"url":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/08\/NephCure_Simple_Logo_RBG.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@nephcure","twitter_misc":{"Tiempo de lectura":"7 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nephcure.org\/managing-rkd\/treatment-options\/fabhalta-iptacopan-for-c3g\/","url":"https:\/\/nephcure.org\/managing-rkd\/treatment-options\/fabhalta-iptacopan-for-c3g\/","name":"FABHALTA\u00ae (Iptacopan)\u00a0for C3G - NephCure","isPartOf":{"@id":"https:\/\/nephcure.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nephcure.org\/managing-rkd\/treatment-options\/fabhalta-iptacopan-for-c3g\/#primaryimage"},"image":{"@id":"https:\/\/nephcure.org\/managing-rkd\/treatment-options\/fabhalta-iptacopan-for-c3g\/#primaryimage"},"thumbnailUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/08\/NephCure_Simple_Logo_RBG.jpg","datePublished":"2026-08-31T15:29:44+00:00","dateModified":"2026-08-31T15:40:53+00:00","description":"Obtenga m\u00e1s informaci\u00f3n sobre FABHALTA\u00ae (Iptacopan), un tratamiento aprobado por la FDA para pacientes con nefropat\u00eda por IgA (IgAN) que ayuda a reducir la proteinuria.","breadcrumb":{"@id":"https:\/\/nephcure.org\/managing-rkd\/treatment-options\/fabhalta-iptacopan-for-c3g\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nephcure.org\/managing-rkd\/treatment-options\/fabhalta-iptacopan-for-c3g\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nephcure.org\/managing-rkd\/treatment-options\/fabhalta-iptacopan-for-c3g\/#primaryimage","url":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/08\/NephCure_Simple_Logo_RBG.jpg","contentUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/08\/NephCure_Simple_Logo_RBG.jpg","width":371,"height":467},{"@type":"BreadcrumbList","@id":"https:\/\/nephcure.org\/managing-rkd\/treatment-options\/fabhalta-iptacopan-for-c3g\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nephcure.org\/"},{"@type":"ListItem","position":2,"name":"Managing RKD","item":"https:\/\/nephcure.org\/managing-rkd\/"},{"@type":"ListItem","position":3,"name":"Treatment Options","item":"https:\/\/nephcure.org\/managing-rkd\/treatment-options\/"},{"@type":"ListItem","position":4,"name":"FABHALTA\u00ae (Iptacopan)\u00a0for C3G"}]},{"@type":"WebSite","@id":"https:\/\/nephcure.org\/#website","url":"https:\/\/nephcure.org\/","name":"NephCure","description":"Para enfermedades renales raras","publisher":{"@id":"https:\/\/nephcure.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nephcure.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nephcure.org\/#organization","name":"NephCure","url":"https:\/\/nephcure.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nephcure.org\/#\/schema\/logo\/image\/","url":"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/03\/cropped-NephCure-favicon-512x512-1.png","contentUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/03\/cropped-NephCure-favicon-512x512-1.png","width":512,"height":512,"caption":"NephCure"},"image":{"@id":"https:\/\/nephcure.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/nephcure\/","https:\/\/x.com\/nephcure","https:\/\/www.instagram.com\/nephcure\/","https:\/\/www.linkedin.com\/company\/nephcure\/","https:\/\/www.youtube.com\/user\/Nephcure"]}]}},"_links":{"self":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/pages\/38961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/users\/12083"}],"replies":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/comments?post=38961"}],"version-history":[{"count":0,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/pages\/38961\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/pages\/24621"}],"wp:attachment":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/media?parent=38961"}],"wp:term":[{"taxonomy":"disease-category","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/disease-category?post=38961"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/topic?post=38961"},{"taxonomy":"treatment-option","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/treatment-option?post=38961"},{"taxonomy":"hf_cat_page","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/hf_cat_page?post=38961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}